LFVN Stock Overview
LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.05|
|52 Week High||US$8.66|
|52 Week Low||US$3.80|
|1 Month Change||-12.34%|
|3 Month Change||-21.51%|
|1 Year Change||-50.31%|
|3 Year Change||-64.78%|
|5 Year Change||-7.75%|
|Change since IPO||-83.47%|
Recent News & Updates
LifeVantage: Soft Quarter, New Dividend Policy, EPS +9% Than Street Expectations
29% net cash of current market capital. Announced first quarterly dividend of $0.03 per share. $28.1 million available under the share repurchase authorization. Revised guidance for 2022. LifeVantage is trading at a P/E of only 4.6x [cash adjusted], with 121% potential upside.
LifeVantage (NASDAQ:LFVN) Might Be Having Difficulty Using Its Capital Effectively
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...
|LFVN||US Personal Products||US Market|
Return vs Industry: LFVN underperformed the US Personal Products industry which returned -25.3% over the past year.
Return vs Market: LFVN underperformed the US Market which returned -10.4% over the past year.
|LFVN Average Weekly Movement||7.5%|
|Personal Products Industry Average Movement||10.2%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: LFVN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: LFVN's weekly volatility (7%) has been stable over the past year.
About the Company
LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name.
LifeVantage Fundamentals Summary
|LFVN fundamental statistics|
Is LFVN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LFVN income statement (TTM)|
|Cost of Revenue||US$38.55m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.75|
|Net Profit Margin||4.49%|
How did LFVN perform over the long term?See historical performance and comparison
Is LifeVantage undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LFVN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate LFVN's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: LFVN is good value based on its PE Ratio (5.4x) compared to the US Personal Products industry average (16x).
PE vs Market: LFVN is good value based on its PE Ratio (5.4x) compared to the US market (15.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LFVN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LFVN is good value based on its PB Ratio (1.5x) compared to the US Personal Products industry average (2.3x).
How is LifeVantage forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if LFVN's forecast earnings growth is above the savings rate (1.9%).
Earnings vs Market: Insufficient data to determine if LFVN's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: LFVN's revenue (2.2% per year) is forecast to grow slower than the US market (8% per year).
High Growth Revenue: LFVN's revenue (2.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LFVN's Return on Equity is forecast to be high in 3 years time (27.8%)
How has LifeVantage performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LFVN has high quality earnings.
Growing Profit Margin: LFVN's current net profit margins (4.5%) are lower than last year (5.3%).
Past Earnings Growth Analysis
Earnings Trend: LFVN's earnings have grown significantly by 29.3% per year over the past 5 years.
Accelerating Growth: LFVN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: LFVN had negative earnings growth (-20%) over the past year, making it difficult to compare to the Personal Products industry average (34.9%).
Return on Equity
High ROE: LFVN's Return on Equity (27.7%) is considered high.
How is LifeVantage's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: LFVN's short term assets ($45.1M) exceed its short term liabilities ($23.6M).
Long Term Liabilities: LFVN's short term assets ($45.1M) exceed its long term liabilities ($14.6M).
Debt to Equity History and Analysis
Debt Level: LFVN is debt free.
Reducing Debt: LFVN has no debt compared to 5 years ago when its debt to equity ratio was 57%.
Debt Coverage: LFVN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: LFVN has no debt, therefore coverage of interest payments is not a concern.
What is LifeVantage current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LFVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LFVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LFVN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LFVN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LFVN has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Fife (60 yo)
Mr. Steven R. Fife, also known as Steve, has served as a President, Director and Chief Executive Officer of LifeVantage Corporation since February 01, 2021. He had been the Chief Financial Officer of Lifev...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD1.61M) is above average for companies of similar size in the US market ($USD770.21K).
Compensation vs Earnings: Steve's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: LFVN's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: LFVN's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
LifeVantage Corporation's employee growth, exchange listings and data sources
- Name: LifeVantage Corporation
- Ticker: LFVN
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Personal Products
- Sector: Household
- Implied Market Cap: US$50.990m
- Shares outstanding: 12.59m
- Website: https://www.lifevantage.com
Number of Employees
- LifeVantage Corporation
- 3300 North Triumph Boulevard
- Suite 700
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.